Literature DB >> 17339249

Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer?

J Trojan, M Stuermer, G Teuber, A Berger, D Faust.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17339249      PMCID： PMC1856813     

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  5 in total

1.  Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.

Authors:  Florian van Bömmel; Bernhard Zöllner; Christoph Sarrazin; Ulrich Spengler; Dietrich Hüppe; Bernd Möller; Heinz-Hubert Feucht; Bertram Wiedenmann; Thomas Berg
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

2.  Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.

Authors:  Scott K Fung; Pietro Andreone; Steve H Han; K Rajender Reddy; Arie Regev; Emmet B Keeffe; Munira Hussain; Carmela Cursaro; Pamela Richtmyer; Jorge A Marrero; Anna S F Lok
Journal:  J Hepatol       Date:  2005-07-07       Impact factor: 25.083

3.  Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.

Authors:  Florian van Bömmel; Thomas Wünsche; Stefan Mauss; Petra Reinke; Alexandra Bergk; Dirk Schürmann; Bertram Wiedenmann; Thomas Berg
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

4.  Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.

Authors:  Christoph Stephan; Annemarie Berger; Amina Carlebach; Thomas Lutz; Markus Bickel; Stephan Klauke; Schlomo Staszewski; Martin Stuermer
Journal:  J Antimicrob Chemother       Date:  2005-11-03       Impact factor: 5.790

5.  Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.

Authors:  Yves Benhamou; Herve Fleury; Pascale Trimoulet; Isabelle Pellegrin; Renaud Urbinelli; Christine Katlama; Willy Rozenbaum; Gwenael Le Teuff; Aldo Trylesinski; Christophe Piketty
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425
  5 in total
  2 in total

Review 1.  Antiviral drug resistance: mechanisms and clinical implications.

Authors:  Lynne Strasfeld; Sunwen Chou
Journal:  Infect Dis Clin North Am       Date:  2010-06       Impact factor: 5.982

2.  Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype.

Authors:  Wenpeng Li; Nadia Warner; Vitina Sozzi; Lilly Yuen; Danni Colledge; Tong Li; Hui Zhuang; Stephen Locarnini; Peter A Revill
Journal:  Hepatol Int       Date:  2012-11-28       Impact factor: 6.047
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.